"The ability to access such a wide range of chemical structures in our virtual screening programmes has been an important aspect of this collaboration"
RiboTargets, a structure-based drug discovery company that develops novel cancer and anti-bacterial therapeutics, has announced that it has extended its exclusive license with Asinex for a further three years.
RiboTargets initially entered into a collaboration with Asinex in mid-2001, giving the company exclusive access to a collection of ~1.75 million compound structures as well as to Asinex's Express Platinum and Gold collections.
Since then, RiboTargets has used its proprietary docking software rDock to identify compounds that have subsequently been provided by Asinex and experimentally verified as hits by RiboTargets.
Dmitry Genis, director of Asinex, commented: "We're delighted to share in the success that RiboTargets has had with our compounds.
The relationship we1ve developed with them has been extremely fruitful for both of us and we look forward to it continuing." David Knowles, RiboTargets's CSO, added: "The ability to access such a wide range of chemical structures from Asinex in our virtual screening programmes has been an important aspect of this collaboration.
Furthermore, the skill of Asinex's synthetic chemists has been instrumental in being able to expand the initial hits, generating vital SAR to help guide subsequent progress.
The relationship demonstrates the benefits of two commercial companies combining their respective skills to mutual benefit."
